H1 2026 Results & 2026 outlook

Pierre BOULUD | CHIEF EXECUTIVE OFFICER
Guillaume BOUHOURS | CHIEF FINANCIAL OFFICER

July 28th 2026

Agenda

Disclaimers

This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.

The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or under taking to update or otherwise revise such information.

This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.

H1 2026 KEY HIGHLIGHTS

H1 2026 – Key Highlights

SALES
€1,965m
+0.2%[1]

CONTRIBUTIVE EBIT
€313m
15.9%
of sales

FREE CASHFLOW
€299m
+76% vs H1 2025
Cash positive

- **Sales growth accelerated in Q2 (+5%[1], +7.3% excl. respiratory panel sales) from Q1 26 (-3.9%) which was impacted by low respiratory epidemiology**
- **CEBIT declined by 5% organically, reflecting modest organic sales growth in H1 26**
- **Sustained focus on innovation with multiple products' launches and Accellix acquisition**
- **Strong cash flow generation: +76% vs H1 2025 at €299m**

[1] *At constant exchange rates and scope vs H1 2025*

H1 2026 – On-going implementation of the GO.28 initiatives

FOR GROWTH

REINFORCING OUR LEADERSHIP IN HIGHPLEX MOLECULAR

BIOFIRE® : GI.1.1 panels FDA submission

ACCELERATION IN POINT OF CARE

SPOTFIRE® : Vaginitis panel FDA submission & mini respi panel CE marking

SPINCHIP®: Hs- Troponin CE Marking

CONTINUOUS INNOVATION IN INDUSTRIAL APP.

GENE-UP® TYPER salmonella launch

ACCELIX acquisition

SMARTBIOME launch

SIMPLE

HEADCOUNTS EVOLUTION CONTROL

SG&A EFFICIENCY

MARKETING, FINANCE & CUSTOMER SERVICE: on-going implementation of new operating models

AI DEPLOYMENT: new chief data officer, bots for several departments

SPAN & LAYERS: on-going actions

COGS IMPROVEMENTS

AUTOMATION : ~60% of BIOFIRE® pouches manufactured on fully automated lines

PROCUREMENT SAVINGS > *€10m*

STRONGER

STRONG EMPLOYEES' ENGAGEMENT

3RD YEAR IN A ROW WITHIN TOP 25%

Engagement Survey Results

PROTECT PROGRAM

Protect everyone, every day, everywhere

RESPONSIBLE

ON TRACK TO REACH THE CSR AMBITION

-31%

IN GHG ABSOLUTE EMISSIONS

vs. 2023 (scope 1&2)

75.5%

OF PROCUREMENT SPEND COVERED BY SUPPLIERS WITH A CSR ASSESSMENT

79/100

ETHICS SCORE OF ECOVADIS

** MyShare: worldwide employee share ownership plan*

*** Per € million of revenue*

Q2 2026
BUSINESS HIGHLIGHTS

Q2 26: solid +5%* sales growth

GO·28 Growth drivers: +8.5%*

BIOFIRE® non-respiratory
+7%*
- Installed base expansion
- On-going cross selling strategy

SPOTFIRE®
+38%*
- +40%* in reagents' sales
- 7,200 instruments (June 26): +60% vs June 2025

MICROBIOLOGY
+6.5%*
- Strong dynamic in Blood Culture
- Price increase

INDUSTRIAL APPLICATIONS
+9%*
- Reagents sales up double digit
- Price increase

BIOFIRE® Respiratory Panels
-6%*
- Lower respiratory epidemiology in Q2 26 vs Q1 25
- Price erosion < 3pp

Immunoassays
-1%*
- Increase in sales excl. China & PCT**
- VIDAS® KUBE instrument: dynamic sales

At constant Exchange Rates and Scope vs H1 2025
*** PCT sales = ~17% of H1 26 immunoassays' sales*

H1 2026 Financial Performance

H1 2026 sales: stable evolution despite a challenging respiratory season

Sales growth % are expressed at constant exchange rates

SPOTFIRE +22%
- **7,200 instruments** installed at the end of June 2026
- Reagents sales up +35%

MICROBIOLOGY +4%
- **+5% excl. China**
- **Strong dynamic** in BACT/ALERT® reagents sales

BIOFIRE® Instr. & Services -6%

BIOFIRE® Non-RP +5.5%
Successful cross-selling strategy

BIOFIRE® RP -16.5%
Low epidemiology in H1 26
Continued leadership in the most competitive segment of syndromic



IMMUNOASSAYS -3%
- **Slight growth excl. China & PCT**

INDUSTRIAL APP. +7%
- **Reagents sales up double digit**
- **Price increase**

OTHERS

H1 2026 sales by geography



NORAM -1%*

€888m

45% of sales

Sales growth in Industrial Applications, microbiology and BIOFIRE® non-RP panels

EMEA +2%*

€647m

33% of sales

Sales growth driven by Molecular (BIOFIRE® non-RP panels), Industrial Applications, and Microbiology

LATAM +11%*

€142m

7% of sales

Sales growth in all Clinical ranges and in Industrial Applications

ASPAC -3%*

€287m

15% of sales

Decline in China and BIOFIRE® RP sales, partly offset by sales growth in Microbiology and Ind. Applications

** At constant exchange rates*

HY 2026 P&L: reported CEBIT[2] down -5% like-for-like[1]

In €m	**H1 2026**	% sales	**H1 2025**	% sales	% Change	% Change LFL(1)
Net sales	1,965		2,044		**- 3.9%**	**+ 0.2%**
Gross profit	1,098	*55.9%*	1,167	*57.1%*	**- 5.9%**	**-1.1%**
SG&A	-544	*27.7%*	-569	*27.8%*	- 4.3%	- 2.1%
R&D	-257	*13.1%*	-249	*12.2%*	+ 3.2%	+ 5.0%
CEBIT (2)	**313**	*15.9%*	**372**	*18.2%*	**-15.7%**	**-4.9%**

- **Gross Profit decreased by -**1% on a like-for-like basis (a -70bps margin evolution on a like-for-like basis) mainly driven by unfavorable product mix, investments in manufacturing projects and higher transport costs due to Middle East events.
- **SG&A** decreased by 2% on a like-for-like basis, reflecting lower variable compensation and positive impact of efficiency measures.
- **R&D** increased by 5% on a like-for-like basis reflecting the sustained investment in Molecular, SPINCHIP® technology and microbiology.
- **CEBIT** was down -4.9% on a like-for-like basis vs H1 2025. The reported amount includes a -€35 million negative currency effect in H1.

(1) Like-For-Like: at constant exchange rates and scope
(2) CEBIT: contributive operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs

H1 2026 P&L: CEBIT to EPS

In €m	H1 2026	% *sales*	H1 2025	% *sales*	% change as reported	% Change LFL(1)
CEBIT	313	*15.9%*	372	*18.2%*	- 15.7 %	-4.9%
Amortization of acquired intangible assets & related expenses	-14		-163			
Operating income before non recurring items	299	*15.2%*	209	*10.2%*	+ 43.3%	
Net financial expense	-5		4			
Income tax *(effective tax rate)*	-69	*-23.4%*	-53	*-24.7%*		
Net income, group share (2)	***226***	*11.5%*	***161***	*7.9%*	**+ 40.5%**	
EPS, diluted	€ 1.91		€ 1.35			
Adjusted EPS (diluted)3	**€1.99**		**€ 2.39**		**-16.7%**	**-4.0%**

- **Amortization of acquired intangible assets** improved by €149m, as reported, vs H1 25 which was impacted by the partial impairment of the Specific Reveal technology
- **Net financial expense of €5m vs income of €4m in H1 2025,** reflecting the impact on cash positions of the stronger euro in H1 2026
- **Effective tax rate of 23.4%: -**130bps vs H1 2025
- **Adjusted EPS**: -4% like-for-like, in line with the CEBIT evolution

(1) *Like-For-Like: at constant exchange rates and scope*

(2) *Excluding minority interest*

(3) *Adjusted Earnings Per Share: Adjusted Net Income divided by the weighted average number of shares outstanding over the period (after deducting shares to be granted to employees under free share plans and treasury shares held for market-stabilization purposes)*

STRONG FREE CASH FLOW: up +€130m vs H1 2025

Millions €	June 2026	June 2025
EBITDA [1]	440	495
Working capital requirement	19	- 75
Tax payment	- 28	- 123
Investments	- 137	- 150
Other cashflows from operation	5	23
Free cash flow [2]	**299**	**170**
Business Dev. & financing activities	- 48	- 118
Dividends	- 115	- 106
Impact of currency changes on net debt	10	- 24
Lease debt	- 18	- 8
Cash flow net	+ 128	- 85
Total net cash (debt)	**+236**	**- 126**

- **Receivables (+€63m)**: efficient cash collection, especially in the US, combined with sales effect
- **Inventories (+€7m)** driven by raw material inventory optimization in the US
- **Fiscal & social debt (-€42m):** payment of 2025 variable compensations
- **Tax Payment (+96m):** favorable cash impact of the 2025 US Tax reform
- **Capex 7.1% of sales:** investments in Manufacturing to increase capacity and automation + placements of new instruments (mainly SPOTFIRE®)
- **Business Dev. (-€28m):** acquisition of Accellix in 2026
- **Financing activities (-€19m):** treasury shares buyback
- **Net Cash position: +€236m**

(1) Earnings before interest, taxes, depreciation and amortization
(2) Sum of cash flow from operating activities and net cash flow used in investing activities

2026 Outlook

2026 FULL YEAR GUIDANCE

GUIDANCE

SALES

+3% to +5%
Organic evolution

Q1 26 Actual:-3.9%
Q2 26 Actual:+5.0%

cEBIT[1]

+0% to +10%
Organic evolution

CAPEX

~8%
of consolidated sales

ASSUMPTIONS

- **Microbiology** +3%* to +5%*
- **BIOFIRE® non RP** ~+8%*
- **SPOTFIRE®** ~+35%* to +45%
- **Industrial Applications** ~+7%* to +9%*
- **Immunoassays** -5%* to 0%*
- **BIOFIRE® respiratory panels** ~ -8%* to -3%*

- **FX impact: -€40 to €-50m on FY 26 CEBIT**
  (previously -€50m / -€60m)
- **Assuming no new oil price spike from Middle East events**

[1]CEBIT: Contributive Operating Income before non-recurring items
** At constant exchange rate*

2027 & 2028 ambitions

Continue to execute on GO.28 pillars with adjusted financial targets reflecting the geopolitical and macroeconomic environment

GO for Growth

- **Aiming at +3% to +6% annual sales growth** at constant exchange rates and scope **in 2027 and 2028**
- Focus on **GO.28 growth drivers**

GO Simple

- Continue the implementation of the **50+initiatives of the plan**
- **Organic annual CEBIT growth higher than organic sales growth in 2027 and in 2028**

GO Stronger

- **On-going reinforcement of team members' engagement** through empowerment, delegation and simplification

GO Responsible

BIOMÉRIEUX

- **CO^2 reduction: -35% by 2028 (Scopes 1 &2)** *vs 2019*
- **+60% Dx results in low & lower-middle income countries** *vs 2023*

GO FOR GROWTH

2027 & 2028 ambitions

GO for GROWTH – 2027 & 2028 SALES GROWTH AMBITION

BIOFIRE® Non-RP

+4%[1] to 8%[1]

BIOFIRE® RP

~-5%[1]

at stable respiratory season

SPOTFIRE®

~+25%[1] to +40%[1]



Microbiology

+3%[1] to +5%[1]

Immunoassays

~-5%[1] to 0% [1]

Industrial Applications

+7%[1] to +9%[1]

Aiming at +3% to +6% [1] annual organic sales growth in 2027 & 2028

[1] *At constant Exchange Rate*

BIOFIRE® non-respiratory panels: leveraging the superior solution to address untapped geographies and segments

bioMérieux ambition:

+4%* to +8%*

annual sales growth in 2027 & 2028

Best in Class Solution

- **Fastest Time to Result**: ~1 hour (non-RP)
- **Largest** menu in the market
- **Fireworks** unique software allowing real-time epidemiology monitoring (cyclosporiasis, …)
- **Leading** installed base: 28.5k units (Dec. 2025) *Over +3,000 in 2 years*
- **5-Star customer service:** regional repair centers

Expand into new segments and geographies

- **Cross selling**
- Globalisation **OUS**
- **Market access** investments to further demonstrate the value of highplex

Innovation

- **GI Mid** panel in 2025
- **GI 1.1** panel in 2026
- **ME 2** panel in 2027

* *At constant Exchange Rate*

SPOTFIRE® sales growth: continue to gain market shares leveraging the unique features of the solution & the menu expansion

bioMérieux ambition:

+25%* to +40%*

annual sales growth in 2027 & 2028

BEST IN CLASS SOLUTION

- Uniquely positioned with **100% of assays CLIA Waived** to truly address the PoC market
- **Fastest Time To Result** : ~15mns
- Most **comprehensive** respiratory menu:
  - 5-plex / 15-plex
  - Strep A embedded

INSTALLED BASE EXPANSION

- **7,200 instruments** as of June 2026
- +60% increase in 12 months

INNOVATION

- **VAGINITIS panel**: FDA submission in Q2 26
- **STI** (*Sexually Transmitted Infection*) panel in 2028
- **MENINGITIS** panel in 2028

* *At constant Exchange Rate*

MICROBIOLOGY sales: leveraging AMR market growth and innovation continued upgrades

bioMérieux ambition:

+3%* to +5%*

annual sales growth in 2027 & 2028

AMR**/AMS*** trend

- **> 1m deaths per year** as a result of AMR
- Expected to reach ~10m by 2050
- **Blood culture** practice **normalization** post bottles supply challenges

MARKET LEADER

- Fully **integrated offer** from ID to AST
- Fast ID with BIOFIRE® BCID and fast AST with VITEK® Reveal

INNOVATION

- Leverage instruments' **launches:**
  - **VITEK® COMPACT PRO**
  - **VITEK® REVEAL ramp up**
  - **VITEK® PRO** in 2027
  - **BACT/ALERT® 3D *next generation*** *in 2028*

CHINA (10% of microbiology sales)

- Manufacturing **localisation:**
  - BacT bottles & VIRTUO® instrument
  - VITEK COMPACT PRO® instrument

** At constant Exchange Rate*
*** AMR: AntiMicrobial Resistance*
**** AMS: AntiMicrobial Stewardship*

Industrial applications to grow +7/9% annually[1] to 2028 by bringing innovation in dynamic segments

bioMérieux ambition:

+7%* to +9%*

annual sales growth in 2027 & 2028

Strong underlying macro trends

- **Growing and ageing population**
- **Worldwide increase in regulatory pressure**
- **Digitalization and automation of testing methods**

Innovation

- **Molecular: GENE-UP®, Mycoplasma**
- **Point of Need (Accellix)**
- **Data & Genomics**

Expansion in dynamic segments

- **Cell & Gene Therapies**
- **mRNA**
- **Food molecular**

* *At constant Exchange Rate*

BIOFIRE® RP & IMMUNOASSAYS: maximizing value from established franchises

~-5%*

annual sales evolution in 2027 & 2028
at stable respiratory season

OPPORTUNITIES

- Growth potential from OUS expansion of the BIOFIRE® franchise
- Leverage High respiratory seasons

HEADWINDS

- Price erosion
- Low respiratory seasons

~-5%* to flat*

annual sales evolution in 2027 & 2028

CAPTURE GROWTH IN DYNAMIC MARKETS

- India, Africa & Latam

INNOVATION

- **New VIDAS® assays** in 2027: Insulin, Folate, Galactomannan
- Leveraging **VIDAS® KUBE** ramp-up
- **SPINCHIP®:** entering the Cardiac PoC segment with the **hs-cTnI** assay in 2027

PERSISTENT HEADWINDS

- PCT & China market

* *At constant Exchange Rate*

GO SIMPLE

2027 & 2028 ambitions

CEBIT to grow organically higher than organic sales growth

GO SIMPLE

50+ initiatives
to strengthen the operating leverage

COGS

- Automation
- Internalization
- Procurement

G&A / R&D

- Process automation
- New operating models
- Focused investments

S&M

- Customer service efficiency
- Launch excellence program
- Digital Marketing

GO STRONGER

2027 & 2028 ambitions

PIONEERING DIAGNOSTICS

CONTINUE TO STRENGTHEN TEAM MEMBERS' ENGAGEMENT

REINFORCED DELEGATIONS

CLEAR ASSIGNMENT OF DECISION-MAKING ROLES

DEPLOYMENT OF 5 CORE BEHAVIORS

CORE PROCESSES SIMPLIFICATION

Be in the

1st quartile

for employees' engagement across healthcare industries

GO RESPONSIBLE

2027 & 2028 ambitions

PIONEERING DIAGNOSTICS

2028 CSR ROADMAP

HEALTH

ACCESSIBILITY

% of patient results supporting AMS in low & lower-middle income countries

TARGETS vs. 2023
2028: **+60%**

ANTIMICROBIAL STEWARDSHIP - AMS

% of referenced antibiotics addressed by our AST solutions

2028 TARGET
≥90%

PLANET

NET ZERO CO_{2e} BY 2050

Reduction in GHG emissions

TARGETS vs. 2023
SCOPES 1&2: -62% *in 2034*, **-35%** *in 2028*
SCOPE 3: -35% *in 2034*

PRODUCT ENVIRONMENTAL PERFORMANCE

Reduction in Virgin plastic and Energy Consumption

TARGETS 2034 vs. 2023
Virgin plastic: -25% (**-5%** in 2028)
Energy consumption: -25% (**-8%** in 2028)

TEAM MEMBERS

SAFETY

Improve Total Recordable Incident & Occupational Illness Rate and Mental Health Index

TARGET:
Improve year on year

DIVERSITY, EQUITY & INCLUSION

Living wage

Gender wage gap

TARGET:
Ensure living wage to all team members &
reduce gender wage gap

BUSINESS CONDUCT

ETHICS

Ethics score of Ecovadis

TARGET 2028
≥75/100

PROCUREMENT

% of procurement spend covered by suppliers with a CSR assessment

TARGET 2028
75% coverage

COMMUNITIES

PHILANTHROPY

net income attributable to the parent company dedicated to philanthropy

TARGET
≥1.5%

SHARING MEDICAL KNOWLEDGE

% in medical education activities & reach

TARGET 2028
+25% vs. 2023

Key Take Aways

Key Take Aways

- **Solid Q2 2026 performance:** +5% organic sales growth

- **Confirmation of the 2026 guidance:**
  - Sales expected to grow between +3% to +5% organic
  - CEBIT expected to grow between +0% and +10% organic
  - FX impact: ~-€40m to -€50m

- **Adjustement of 2027 and 2028 financial perspectives:**
  - Organic sales growth expected to be between +3% to +6%
  - Organic CEBIT growth expected to be higher than organic sales growth

- **Investing for the future**: SPOTFIRE® Vaginitis, BIOFIRE® GI1.1, SPINCHIP®, new instruments in microbiology, GENE-UP® TYPER…

PIONEERING DIAGNOSTICS

MAIN CSR KPIS FOLLOW-UP

AS OF END OF JUNE 2026

HEALTH	PLANET	TEAM MEMBERS	BUSINESS CONDUCT	COMMUNITIES
ACCESSIBILITY	**NET ZERO CO_{2e} BY 2050**	**SAFETY**	**ETHICS**	**PHILANTHROPY**
+45% patient results supporting AMS in low & lower-middle income countries vs Q1'23	In absolute value vs. 2023: **SCOPES 1&2: -31%** SCOPE 3: N/A	**TR2IR: 0.52** *2025: 0.8* Mental Health Index: **N/A** *2025: 8.1*	**N/A** *2025: 79/100*	**N/A** *2025: 1.34%*
TARGETS vs. 2023 2028: **+60%**	*TARGETS vs. 2023* SCOPES 1&2: -62% in 2034, ***-35%** in 2028* SCOPE 3: -35% in 2034	*TARGET:* Improve year on year	*TARGET 2028* Ethics score of Ecovadis **≥75/100**	*TARGET* **≥1.5%** of net income attributable to the parent company dedicated to philanthropy
ANTIMICROBIAL STEWARDSHIP - AMS	**PRODUCT ENVIRONMENTAL PERFORMANCE**	**DIVERSITY, EQUITY & INCLUSION**	**PROCUREMENT**	**SHARING MEDICAL KNOWLEDGE**
N/A **2025:** EUCAST: **92.4%** CLSI: **96.3%**	**N/A**	No team member under **living wage** **Gender wage gap N/A**	**75.5%** of procurement spend covered by suppliers with a CSR assessment **68.3** weighted average score	**N/A**
2028 TARGET **≥90%** of referenced antibiotics addressed by our AST solutions	*TARGETS 2034 vs. 2023* Virgin plastic: -25% (**-5%** in 2028) Energy consumption: -25% (**-8%** in 2028)	*TARGET:* Ensure living wage to all team members & reduce gender wage gap	*TARGET 2028* **75%** coverage **69** score	*TARGET 2028* +25% in medical education activities & reach vs. 2023